Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency
Prime Medicine announced FDA clearance of its Investigational New Drug application for PM647, an in vivo Prime Editor targeting the genetic root of Alpha-1 Antitrypsin Deficiency (AATD). The clearance enables initiation of a global Phase 1/2 clinical trial expected to deliver initial data in 2027. PM647 aims to provide a one-time curative therapy a…